Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity
一项将趋化因子靶向治疗与局部区域化疗免疫疗法相结合治疗复发性铂敏感卵巢癌的I期临床试验显示，CXCR3配体和1型免疫标志物均被诱导表达。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-3659
Orr, Brian; Mahdi, Haider; Fang, Yusi; Strange, Mary; Uygun, Ibrahim; Rana, Mainpal; Zhang, Lixin; Suarez Mora, Adria; Pusateri, Alexandra; Elishaev, Esther; Kang, Chaeryon; Tseng, George; Gooding, William; Edwards, Robert P; Kalinski, Pawel; Vlad, Anda M
